Eris Lifesciences Partners with Natco Pharma to Commercialize Semaglutide in India 

Key Highlights: 

• Eris Lifesciences has partnered with Natco Pharma to commercialize Semaglutide in India, strengthening its presence in the diabetes and metabolic care segment as demand for advanced therapies continues to rise. 
• As part of the collaboration, Natco Pharma has received approval from the Central Drugs Standard Control Organisation to manufacture generic semaglutide for the Indian market, with a commercial launch expected in March 2026 targeting the treatment of Type 2 Diabetes. 
• The partnership combines Natco’s manufacturing and regulatory expertise with Eris’s strong commercial footprint in diabetology, where the company engages closely with endocrinologists and physicians across India. With rising rates of diabetes and obesity, semaglutide-based therapies are expected to play an expanding role in metabolic disease management. 

Implications: 

Semaglutide generics could slash Novo Nordisk pricing by 70-80% in India’s $2.5B diabetes market (12% CAGR), capturing 25%+ share and pressuring chronic therapy incumbents like Sun Pharma. 
Eris/Natco combo accelerates GLP-1/obesity adoption amid 100M+ T2D cases. 
Launch reinforces India’s generics export edge to Saudi/MENA, challenging Ozempic/Wegovy patents post-2026. 

Source: Expresspharma